Thursday, May 12, 2016

The Smoothie of Tomato, Blueberry and Green tea drink for reduced Risk and Treatment of Amyloid diseases (primary amyloidosis)

Kyle J. Norton(Scholar, Master of Nutrients), all right reserved.
Health article writer and researcher; Over 10.000 articles and research papers have been written and published on line, including world wide health, ezine articles, article base, healthblogs, selfgrowth, best before it's news, the karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as international journal Pharma and Bio science, ISSN 0975-6299.

The smoothie for prevention and treatment of  Amyloid diseases
Yield: 2 servings (about 8 ounces each)

1/2 cup tomato
1 cup blueberry
1 cup green tea drink (Make from 4 grams of green tea, a slice of ginger and a cup of hot water lipped for 5 minutes, and let cool to room temperature)

1. Place all ingredients in a blender and puree about 1 minute
2. Blend on high speed about 1 minute or until the mixture is thick and the ice is well crushed.
3. Serve immediately

The finding of a natural source for treatment of Amyloid diseases has been running into many obstacles, many ingredients showed initially with promising result in animal studies have not produced same potentials in large sample size and mutli centers human trials.
Amyloid diseases is a condition of abnormal proteins build up in the body tissues and organs.

Recent studies back by well known institutions proposed, Tomato, Blueberry and Green tea drink may be the next generation of natural ingredients for prevention and treatment of Amyloid diseases.
Green tea has been a precious drink in traditional Chinese culture and used exceptional in socialization for more than 4000 thousand years. Because of their health benefits, they have been cultivated for commercial purposes all over the world. According to joint study led by the Tokushima University Graduate School, polyphenol (-)-epigallocatechin-3-gallate inhibited amyloid fibril formation of various amyloidogenic proteins in induction of cytotoxicity(1). The antioxidant also impeded the amyloid fibrils formed by proteolytic fragments of prostatic acid phosphatase, through its anti-viral properties(2).
Dr. Zlatic CO. and colleagues at the The University of Melbourne, in the investigation of Epigallocatechin Gallate effect against protein misfolding and aggregation, leading to amyloid fibril formation, said, "EGCG significantly altered the size distribution of fibrils, most likely by promoting the lateral association of fibrils and subsequent formation of large aggregates"(3).

Resveratrol, a phytochemical in the class of Stilbenoids, found abundantly in grape and blueberry may also benefits patients with Amyloid diseases through inhibition of amyloid formation by islet amyloid polypeptide(4). On damages of mouse cortical neurons resveratrol exhibited neuro protective effects through SIRT1/Akt1 neuroprotective pathway in tumorigenesis via increased cell viability and reduced the number of apoptotic cells(5).
Dr. Granzotto A and Dr. Zatta P said, "resveratrol (May be) a neuroprotectant in dementia in relation to the oxidative stress produced by amyloid and metal dysmetabolism"(6).

Carotenoids, an derivative of vitamin A found abundantly in tomato also expressed significantly anti degenerative diseases mediated by oxidative stress induced amyloids deposition and fibril formation(7) in patients with Alzheimer's Disease (AD). 
Lycopene, a member of arotenoids also protected mitochondria against Aβ-induced damages against neurotoxicity by inhibiting mitochondrial oxidative stress and improving mitochondrial function, according to study led by the Center for Diseases Prevention and Control of the Rocket Force of PLA(8).

The effectiveness of  Green tea, Tomato and Blueberry may serve as cornerstones of pharmaceutical target for further studies in production of a potential medication for reduced risk, complications and treatment of Amyloid diseases (primary amyloidosis)  with little or no adverse effects.

People who are at high risk of Amyloid diseases (primary amyloidosis)  due to aging, weaken reno function... should drink at least one serving daily and women with Amyloid diseases (primary amyloidosis)  should drink no more than 4 servings daily, depending to digestive toleration.

Life style and diet pattern change are necessary.



References
(1) The polyphenol (-)-epigallocatechin-3-gallate prevents apoA-IIowa amyloidosis in vitro and protects human embryonic kidney 293 cells against amyloid cytotoxicity by Nakajima H1,2, Nishitsuji K1, Kawashima H3, Kuwabara K1,2, Mikawa S2, Uchimura K4, Akaji K3, Kashiwada Y5, Kobayashi N6, Saito H2, Sakashita N1.(PubMed)
(2) Epigallocatechin-3-gallate rapidly remodels PAP85-120, SEM1(45-107), and SEM2(49-107) seminal amyloid fibrils by Castellano LM1, Hammond RM2, Holmes VM3, Weissman D3, Shorter J4.(PubMed)
(3) Fluphenazine·HCl and Epigallocatechin Gallate Modulate the Rate of Formation and Structural Properties of Apolipoprotein C-II Amyloid Fibrils by Zlatic CO1, Mao Y1, Ryan TM1, Mok YF1, Roberts BR1, Howlett GJ1, Griffin MD1.(PubMed)
(4) Mutational analysis of the ability of resveratrol to inhibit amyloid formation by islet amyloid polypeptide: critical evaluation of the importance of aromatic-inhibitor and histidine-inhibitor interactions by Tu LH1, Young LM, Wong AG, Ashcroft AE, Radford SE, Raleigh DP.(PubMed)
(5) Neuroprotective effects of resveratrol on damages of mouse cortical neurons induced by β-amyloid through activation of SIRT1/Akt1 pathway by Zhang J1, Feng X, Wu J, Xu H, Li G, Zhu D, Yue Q, Liu H, Zhang Y, Sun D, Wang H, Sun J.(PubMed)
(6) Resveratrol and Alzheimer's disease: message in a bottle on red wine and cognition by Granzotto A1, Zatta P2.(PubMed)
(7) Carotenoids and Alzheimer's disease: an insight into therapeutic role of retinoids in animal models by Obulesu M1, Dowlathabad MR, Bramhachari PV.(PubMed)

No comments:

Post a Comment